PARTICULAR DIAGNOSIS AND TREATMENT FEATURES OF A CASE OF COMMON VARIABLE IMMUNOGLOBULIN DEFICIENCY ASSOCIATED WITH GLUTEN INTOLERANCE AND SEVERE MALABSORPTION SYNDROME

Georgescu A.1, Georgescu D.2, Dorobanțu D.3

1 Infectious Diseases Clinic, University of Medicine and Pharmacy Targu-Mures
2 Gastroenterology Department, University of Medicine and Pharmacy Targu-Mures
3 Department of Plastic and Reconstructive Surgery, Emergency County Hospital Mures

Abstract. The authors present the case of a Common variable immunoglobulin deficiency (CVID) patient who has hypogammaglobulinemia, bowel involvement and severe malabsorption syndrome. Various problems related to positive and differential diagnosis are discussed within the framework of a very severe progression due to malabsorption syndrome with cachexia, numerous intercurrent pulmonary, intestinal, genital and skin infections and thrombophilia secondary to malabsorption. Eventually the course of disease is favourable partially thanks to the multidisciplinary approach undertaken.

Keywords: immunodeficiency, enteropathy, gluten, malabsorption, thrombophilia

Introduction

Specific to the common variable immunoglobulin deficiency syndrome (CVID) is the low level of serum immunoglobulins despite the normal number and morphology of the B lymphocytes. The incidence of the disease varies widely between 1:10,000 and 1:200,000, having an equal distribution among sexes [1, 2]. The late onset of intercurrent infections, usually in adolescence lead to the term “acquired hypogammaglobulinemia” although the conditions seems to have genetic origins causing altered lymphocyte B functionality [1,3]. Besides recurrent infections, oftentimes with opportunistic germs, the disease can involve various organs and systems; it can be associated with numerous autoimmune and granulomatous conditions and is quite often seen together with cancers of the hematopoietic system and the digestive tract, thus creating difficult differential diagnosis problems [4,5]. In spite of severe infections and organ complications, the diagnosis is established late most of the times, 1-10 years after the initial symptoms [5].

A multidisciplinary approach is necessary in order to diagnose and treat these patients in an effective manner [1].

Case report

Male patient, aged 32, presented with serious weight loss over the last year (10 kg) and diarrheic, liquid stools. No immunodeficiency or celiac sprue was present in family members. The patient suffered from viral hepatitis A one year ago, and repeated respiratory infections over the last years in the absence of smoking or alcohol as risk factors. The physical examination showed a cachectic patient (Body mass index - BMI 12.7), hyperpigmentation of the skin, missing subcutaneous adipose tissue, calf oedema, no peripheral adenomegaly palpable liver and spleen.

The initial biological evaluation showed light anaemia, (hemoglobinemia: 121 g/L), with low serum iron levels (6.26 µmol/L) but normal mean cell volume (MVC 91.3 fL), white blood cell count 8420/mm³ with a normal leukocyte formula, normal morphology on the peripheral blood smear test, thrombocytes 153,000/mm³, low levels for the serum immunoglobulins: IgG 20 UI/ml, IgM 16 UI/ml, IgA undetectable. Immunophenotyping the leukocytes in peripheral blood flow shows no decrease of B: CD19+ 8%, CD56+ 2%, CD3+ 88% (30% Th, 58%Tc; Th/Tc 0.58), CD4 34.50%, CD4/
The combined occurrence of a severe immunoglobulin G deficit with normal lymphocyte B morphology and recurring infec-
tions is suggestive of a common variable immunoglobulin deficit. The bowel mucosa aspect combined with diarrhea and malabsorption seemed to indicate a celiac disease.

The differential diagnosis of the immune deficit focused on selective IgA deficit (which could precede CVID) [6], X-linked agammaglobulinemia (decrease in number of lack of peripheral B cells, light hypogammaglobulinemia) [1,7], hyper IgM syndrome (increase of IgM, lymphocyte B alterations) [8,9].

The patient was soon started on iv immunoglobulin until the low end of the range was reached, then maintained for 6 months; metronidazole to treat the Giardia lamblia infestation, without improvement – malabsorption syndrome and diarrhoea were still present. Then we considered gluten enteropathy as a possibility, making the change to a gluten free diet without any obvious subjective improvement over the following 6 months but with a slight his-
tological one. Given the lack of response to therapy for the celiac disease and the bowel autoimmune manifestations caused by CVID the patient was given oral corticotherapy, Prednisone 15mg/day. The evolution was positive, an improvement of the diarrheic syndrome and nutrition overall aggravated by recurrent respiratory infections.

The low compliance to gluten free diet led after 2 years of steady progress to deterioration in the nutritional status and repeated respiratory infec-
tions, the most common agents that were isolated being Haemophilus influenzae, Pseudomonas aeruginosa, Klebsiella pneumoniae. The antibiotic therapy worked well, no secondary bronchiectasis developed. Other infectious episodes included orchiepididymitis, otitis media, leg skin infections suggesting a streptococcal agent, enteric infections caused by Giardia lamblia each time.

With a background of malabsorption and thrombophilia (protein S activity 33%, protein C and antithrombin III normal) the patient later developed bilateral iliofemoral deep vein thrombosis with a good response to anticoagulants but with second-
ary necrosis in the right leg, possibly Coumadin necrosis. The necrosis eventually led to loss of skin covering the entire lower limb and repeated surgery, immune and nutritional reanimation and skin grafts with a favourable evolution – the limb recovered its skin and function. The patient was put on low molecular weight heparin for lack of other options with an almost complete repermeabilization of the deep veins in the lower limbs.

The current treatment consists of a hyperproteic, hypercaloric gluten free diet, postural drainage of the lower limbs and kinesiotherapy. The most important therapeutic ingredient is intravenous human immunoglobulin IgG (substitution therapy), the minimal required dose in order to maintain their serum level above the laboratory baseline being 20 grams per month, delivered on a fortnight basis. The patient follows an immunosuppressive treatment with prednisone 10 mg/day and anti-
coagulants – LMW heparins (enoxaparin 2x6000 UI/day). As a side effect of heparins and cortico-
therapy, osteoporotic lesions were noted that are currently treated with bisphosphonates (ibandronic acid 3 mg IV every 3 months), combined with al-
pha D3 1 µg/day and 1000 mg calcium salts. The anti-infective treatment is customized to meet the severity of the infection, its localization and the exact nature of the agent when identified. We don’t use antibiotic prophylaxis. Tianeptine in a dosage of 2x12.5 mg is our antidepressant of choice. Ac-
tive immunoprophylaxis is not indicated due to insufficient antibody. Psychological counselling is crucial to maintain compliance to diet and treat-
ment, to accept prolonged hospital stays, motor, social, professional and family disabilities and to allow for an increase in the overall quality of life. The difficulties associated with getting a good peripheral and central venous access force us to consider a totally implanted device for long term intravenous therapy in the near future.

**Discussions**

Our nosological framework was not accurate
since we couldn’t rule out a selective IgA deficit prior to CVID or an X-linked lymphoproliferative syndrome and we couldn’t explore the Epstein Barr infection given the lack of antibodies and the SH2D1A expression [6, 7]. We had no data to confirm gluten enteropathy, the microscopy showing lymphoid nodular hyperplasia and villi alterations without the typical findings of the celiac sprue. Glandular crypt hypertrophy and villous atrophy were to be expected in such a severe malabsorption syndrome [10]. Moreover the genetic tests for celiac disease were negative but cannot rule out the condition. The good response to a gluten free diet strongly suggested the coexistence of CVID and gluten intolerance, extensively reported in medical literature [1, 2, 7].

A particular feature of the case is the severity of the malabsorption syndrome and of the diarrhoeic syndrome, responding quite well to corticotherapy and gluten free diet. The paradoxical good response to corticotherapy can be explained by the autoimmune involvement of the bowel [1, 3]. Any attempt to do without the corticotherapy led to an immediate aggravation of the condition, especially diarrhoea and malabsorption.

Despite countless infectious episodes, the response to antibiotics has always been very good. The most serious complication was the coumarinic necrosis with a serious risk of losing the lower limb. We want to underline the fact that despite massive skin loss we managed to avoid infection and local suppurration by using isolation measures, asepsis, antisepsis, targeted antibiotic treatment and using the best known reparatory and reconstructive surgical techniques.

Among technical problems we should mention the very difficult IV access, the osteoporosis leading to motor inabilities and teeth loss making certain diets problematic.

Oncological monitoring was another challenge, the risk for lymphoma being 400 times bigger than in general population, and the risk for digestive cancer being also very high [1,7]. We practiced endoscopies and biopsies followed by immunophenotyping each year, also peripheral flow cytometry as often as needed and abdominal echography twice a year. We determined CA 19-9, CA 15-3,CA 72-4, AFP, CEA, tPSA on a yearly basis; in 2011 we recorded a moderate increase in CEA, CA 15-3 and CA 19-9 levels, but cannot confirm an oncologic pathology.

We consider short term prognosis to be good but the long term one remains reserved [4]. The potentially unfavourable evolution leads to suggesting biological therapy with anti TNF alpha antibodies as an option [1, 4, 7].

Conclusions

The common variable immunoglobulin deficit has a wide range of clinical manifestations including various organs and systems. There are real difficulties both regarding the positive diagnosis and treatment which has to be customized to meet the specific needs of the patient. A multidisciplinary approach is crucial in this respect. A great deal of effort is required to increase the quality of life due to the multisystem involvement caused either by disease or by therapy.

Aknowledgments The authors thank Dr. Brânduşa Căpâlnă for her logistic support and introducing the patient into the rare disease program.

References


Therapeutics, Pharmacology and Clinical Toxicology
INFORMATION FOR AUTHORS

The authors are responsible for preparing the manuscript they submit to the Journal exactly according to the instruction. Our instructions are conform to the guidelines of the International Committee of Medical Journal Editors.
Manuscripts which do not follow the format and style of the journal may be returned to the authors for revision.
The editors reserve the right to make literary corrections of manuscripts in the interest of style, clarity and readability.
The content of the published manuscript is read and approved by the authors after editing in accordance with the journal's style. Accepted manuscripts become property of Therapeutics Pharmacology and Clinical Toxicology after having appeared in print. The authors are free to use the material elsewhere with advance notice.
Reprinting will be permitted with quotation of Therapeutic Pharmacology and Clinical Toxicology as the original source and with written permission of the editor. Manuscripts are not returned to the authors.
The manuscript must accompanied by a cover letter including the name (first name, middle initial, last name), institutional or academic affiliation of all authors; address, phone, fax numbers, e-mail of the designated corresponding author. The cover letter must be signed by all authors. Everyone listed as an author of an article must have made a substantial contribution to the manuscript. In case of multiple authors include a brief statement detailing the contribution of each author. Each author(s) must declare that the article is original, hasn't been submitted to another journal and has not been previously published. For previously published materials send written permission to reprint any figure or table. If photographs of patients are used, either the subjects should not be identifiable or their pictures should be accompanied by written usage permission.
Indicate the type of manuscript being submitted (editorial, letter to the editor, systematic review, meta-analysis, clinical trial, original article, case report, adverse reaction) with a brief indication of the importance of the paper.
The authors must describe any direct or indirect financial interest they may have in the subject. The authors must transfer certain copyright to the publisher.

PEER REVIEW PROCESS

The peer review process is applied to all submitted manuscripts.
Manuscripts are examined by the Therapeutics, Pharmacology and Clinical Toxicology’s scientific board and assigned to 2 reviewers.
The recommendations of the reviewers place each paper in one of the following categories:
1. Publish as submitted without revision
2. Publish as submitted with minor revisions
3. Publish pending author changes and rereview
4. Reject for publication.

Corresponding authors are notified of the reviewers’ comment. The authors of the paper must submit a revised version addressing all reviewers’ comments and must include a cover letter explaining how the concerns have been addressed.
The revised paper is sent by the editor to the initial reviewer. If the paper has been revised to the reviewer’s satisfaction, it will be recommended for publication.
The editors communicate the result to the authors. Corresponding author will be receiving an electronic copy of the edited manuscript prior to printing.

ITEMS REQUIRED FOR SUBMISSION

1. Title page:
   a. Category of manuscript,
   b. Long title,
   c. Short title (running head),
   d. Authors’ complete name and affiliation,
   e. Name and address of the correspondence author.
   f. Conflict of interest: indicate all financial support and include a grant or contract numbers, and the complete information of the institution/company,
   g. Brief description,
   h. Abstract,
   i. Keywords
   j. Permission letter (when applicable)
   k. Copyright agreement

2. Signature of all authors
3. Manuscript - the text of the manuscript should be submitted as a single document
4. References
5. Tables and/or figures
Manuscript preparation

All articles must be original material, not previously published and not currently under consideration for publication in another journal. Each paper, including the abstract and references may not exceed 10 pages. The paper should be written in English. Text should be supplied in a format compatible with Microsoft Word (with .doc extension). All manuscripts must be typed left justified only with margins of at least 2,5cm, at double space, in 12 points, Times New Roman or Arial font for normal text and symbol font for all symbols. Indent first line at 10mm. All text should be black-or-white. Do not use colored text. Avoid using „Styles and Formatting” of MS Word.

TITLE: not exceeding 50 characters (including spaces), it should be brief but informative. No abbreviations allowed.

ABSTRACT: a brief summary of the research; include a brief introduction, a description of the tested hypothesis, the approach used to test the hypothesis, the recorded result and the conclusion. No abbreviations allowed, cited.

KEYWORDS: 5-6 specific word, not repeating the title of the manuscript.

TEXT: the text of the original research manuscript should be arranged in the following sections – introduction, materials and methods, results, discussion, conclusions. Introduction: description of the research area, relevant background information, and the hypotheses tested in the study should be included. Materials and methods: materials and subjects utilized in the study as well as the procedures undertaken to complete the work. The methods should be described in sufficient detail if they could be repeated by a competent researcher. Mentioning of the statistical tool used for analysis of the results. All procedures involving experimental animals or human subjects must be accompanied with a statement on the necessary ethical approval from an appropriate ethics committee. Results: should describe the reason for each experiment, the obtained result and its significance. Discussion: relate the results’ section to the current understanding of the scientific problem being investigated; discuss the significance of your result. Avoid the use of footnotes in the text. Use the metric system, SI units to express weight and measures. Clearly indicate the place where the table or figure is to be inserted.

TABLES AND FIGURES: insert title above the table with initial capitals, extra space but no punctuation. They should be numbered in the order of their mentioning in the text. Use Roman numerals for tables and Arabic numerals for figures. Table should be in MS Word. Figures: most figures are in black-and-white, without gridlines. Save as .tiff, .jpeg. The minimal accepted resolution – 300 dpi. Do not place a box or ruled frame around a finished table. Place figures and tables separately, at the end of manuscript, one per page. Any table or figure must have a legend. For graphs Excel graphs are acceptable. Present 2D data and avoid 3D plots.

ACKNOWLEDGEMENTS: can mention people who have helped make your manuscript possible. Mention all applicable grants and other funding that supported your work.

REFERENCES: number consecutively in the order that are cited in the text not in alphabetical order. The list must contain the first six authors (if there are least six) or the first three authors (if more than six) and et all. Articles: authors should be presented: last name, initial of first name. Indicate title of article, name of journal, year of publication, volume and issue number, start-end page. Journal name abbreviation should conform to those used in Index Medicus. If journal is not included in Index Medicus use the entire title of the journal. For articles published in online journals also add the URL and the date when the article was accessed. Books: author of the chapter, title of the chapter, editor, title of book, edition, city and country, publisher, year, specific pages. For web contents list: author, title of the page or content, name or owner of the web site, URL, publication, update, access date. It is the responsibility of the author to verify the accuracy of all references.

ABBREVIATION, ACRONYMS AND SYMBOLS: use only standard abbreviations. Abbreviations must be defined on their first use in the paper – the full term should be spelled out first, followed by the abbreviated term in parentheses.

The article should be submitted to Therapeutics, Pharmacology and Clinical Toxicology

Editorial Office:

Associate Professor dr. Victoria Aramă,

INBI „Prof. Dr. Matei Bals”,

1 Dr. Calistrat Grozovici Str., Sector 2, Bucuresti, CP 021105

or by e-mail at the address: submit@therapeutics.ro
Bank account:
RO 80 BPOS 7060 2559 568 ROL 01
Banc Post Universitate
For: Editura RP

Annual subscription rates for 2011: 100 RON – individual subscription
200 RON – institutional subscription

Frequency: 4 issues a year

Orders should be sent to the Editorial office by E-mail: terapeutica@terapeutica.ro